Cargando…
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance
Autores principales: | Mariottini, Alice, Repice, Anna Maria, Barilaro, Alessandro, Massacesi, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940562/ https://www.ncbi.nlm.nih.gov/pubmed/35318561 http://dx.doi.org/10.1007/s10072-022-05961-9 |
Ejemplares similares
-
Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events
por: Noh, Yunha, et al.
Publicado: (2023) -
Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022) -
Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events
por: Ng, Siew C, et al.
Publicado: (2022) -
Post COVID‐19 vaccination: AusVaxSafety survey participation and adverse events – a community‐based regional Queensland study
por: Hamilton, Elizabeth, et al.
Publicado: (2022) -
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience()
por: Bertozzi, Andrea, et al.
Publicado: (2023)